{"id":9203,"date":"2014-10-11T14:31:03","date_gmt":"2014-10-11T13:31:03","guid":{"rendered":"https:\/\/www.ilmelanoma.com\/cobimetinib\/"},"modified":"2026-10-17T11:23:05","modified_gmt":"2026-10-17T10:23:05","slug":"cobimetinib","status":"publish","type":"page","link":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/cobimetinib\/","title":{"rendered":"Cobimetinib in melanoma"},"content":{"rendered":"<div class=\"im26-diagnosis-guide\">\n<aside class=\"im26-dg-related\"><strong>How to read this guide<\/strong><\/p>\n<p>Educational information based on the cited sources, not an individual prescription. Editorial revision is not equivalent to specialist clinical validation. Decisions and treatments must be agreed with the treating team; benefits, risks and availability depend on the case.<\/p>\n<\/aside>\n<nav class=\"im26-dg-toc\" aria-label=\"On this page\"><strong>On this page<\/strong><\/p>\n<ol>\n<li><a href=\"#med-meccanismo\">What cobimetinib is<\/a><\/li>\n<li><a href=\"#med-indicazione\">Current indication and limitations<\/a><\/li>\n<li><a href=\"#med-cobrim\">What coBRIM demonstrated<\/a><\/li>\n<li><a href=\"#med-controlli\">Adverse effects and planned monitoring<\/a><\/li>\n<li><a href=\"#med-assunzione\">Administration, interactions and daily life<\/a><\/li>\n<li><a href=\"#med-storia\">From research to practice: what remains experimental<\/a><\/li>\n<\/ol>\n<\/nav>\n<section class=\"im26-dg-section\" id=\"med-meccanismo\">\n<h2>What cobimetinib is<\/h2>\n<p>Cobimetinib, marketed as Cotellic, is a targeted treatment inhibiting MEK. It should not be described as conventional cytotoxic chemotherapy. BRAF and MEK belong to the same cellular signalling pathway: blocking it at two points can improve tumour control compared with BRAF inhibition alone.<\/p>\n<p>This biological rationale is not enough to select treatment. Clinical trials measuring benefits and risks and a relevant tumour mutation are required. The authorised melanoma combination is cobimetinib with <a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/vemurafenib-2\/\">vemurafenib<\/a>; its components cannot be freely replaced with other medicines in the same classes. Prescribing remains the responsibility of an experienced oncologist.<\/p>\n<p class=\"im26-dg-sources\"><small>Sources for this section: <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cotellic\">EMA \u2014 Cotellic: indications, product information and leaflet<\/a>; <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25265494\/\">Larkin et al. \u2014 coBRIM, randomized phase 3 (2014)<\/a>.<\/small><\/p>\n<\/section>\n<section class=\"im26-dg-section\" id=\"med-indicazione\">\n<h2>Current indication and limitations<\/h2>\n<p>In the European Union, Cotellic is indicated with vemurafenib in adults with unresectable or <a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/common-types-of-melanoma\/metastatic-melanoma\/\">metastatic melanoma<\/a> positive for a BRAF V600 mutation. Testing must precede selection: the lesion\u2019s appearance, age or skin location cannot establish mutation status. Assessment includes stage, symptoms and previous treatments.<\/p>\n<p>This indication is not an adjuvant authorisation after any excision and must not be transferred to ocular melanoma or other diseases without specific evidence. Immunotherapy alternatives may also exist in BRAF-mutated melanoma. The decision should therefore explain why this pair is proposed, what it aims to achieve and how it fits into the overall treatment pathway.<\/p>\n<p class=\"im26-dg-sources\"><small>Sources for this section: <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cotellic\">EMA \u2014 Cotellic: indications, product information and leaflet<\/a>; <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39550033\/\">ESMO \u2014 Cutaneous melanoma: Clinical Practice Guideline (2024\/2025)<\/a>.<\/small><\/p>\n<\/section>\n<section class=\"im26-dg-section\" id=\"med-cobrim\">\n<h2>What coBRIM demonstrated<\/h2>\n<p>The randomised phase III coBRIM trial enrolled 495 patients with advanced BRAF V600 melanoma, comparing vemurafenib plus cobimetinib with vemurafenib plus placebo. The 2014 publication documented improved progression-free survival, meaning time without worsening or death, with the combination.<\/p>\n<p>The initial report gave medians of 9.9 and 6.2 months; these figures belong to that specific analysis. Updates with different <a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/what-to-do-after-melanoma\/\">follow-up<\/a> can report different medians, as in EMA documentation: these are not necessarily contradictory findings. Tumour response, response duration, progression and overall survival must be distinguished.<\/p>\n<p>The comparison does not prove superiority over every current treatment: the control was vemurafenib alone, not a modern immunotherapy regimen. A trial median is not an individual prediction. Benefit must also be assessed alongside toxicity, which does not disappear when the second medicine is added.<\/p>\n<p class=\"im26-dg-sources\"><small>Sources for this section: <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25265494\/\">Larkin et al. \u2014 coBRIM, randomized phase 3 (2014)<\/a>; <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cotellic\">EMA \u2014 Cotellic: indications, product information and leaflet<\/a>.<\/small><\/p>\n<\/section>\n<section class=\"im26-dg-section\" id=\"med-controlli\">\n<h2>Adverse effects and planned monitoring<\/h2>\n<p>Effects to understand include diarrhoea, nausea, rashes, fever, photosensitivity and abnormal liver tests. Muscle-enzyme elevations and, less commonly, serious muscle problems can occur. Marked muscle pain, unusual weakness or dark urine should be reported without waiting for the next appointment.<\/p>\n<p>Cardiac-function monitoring and attention to eye symptoms are also relevant: blurred vision, spots in the visual field or other changes require prompt assessment. Treatment can cause serious events and require interruption or modification decided by a doctor. Do not automatically attribute every symptom to the medicine: infection and other causes must be considered.<\/p>\n<p>The schedule of tests and visits is individualised. Keeping the centre\u2019s contact details, an updated medication list and written symptom-reporting instructions helps make care safer. In emergencies, seek emergency services and communicate the treatments currently being taken.<\/p>\n<p class=\"im26-dg-sources\"><small>Sources for this section: <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cotellic\">EMA \u2014 Cotellic: indications, product information and leaflet<\/a>; <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zelboraf\">EMA \u2014 Zelboraf: indications, product information and leaflet<\/a>.<\/small><\/p>\n<\/section>\n<section class=\"im26-dg-section\" id=\"med-assunzione\">\n<h2>Administration, interactions and daily life<\/h2>\n<p>Cobimetinib and vemurafenib have different administration instructions: follow the calendar prescribed by the centre. This page does not provide an individual dosing regimen. For a missed dose, vomiting or interruption, consult the instructions supplied and the leaflet; do not independently double or make up doses.<\/p>\n<p>Other medicines can alter cobimetinib exposure. Report antibiotics, antifungals, herbal products and supplements too, without independently stopping necessary medication. Discuss contraception, pregnancy, breastfeeding and reproductive plans before starting. Sun protection remains important: cancer treatment does not remove the need to protect skin and monitor new lesions.<\/p>\n<p class=\"im26-dg-sources\"><small>Sources for this section: <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cotellic\">EMA \u2014 Cotellic: indications, product information and leaflet<\/a>; <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zelboraf\">EMA \u2014 Zelboraf: indications, product information and leaflet<\/a>.<\/small><\/p>\n<\/section>\n<section class=\"im26-dg-section\" id=\"med-storia\">\n<h2>From research to practice: what remains experimental<\/h2>\n<p>Older announcements about cobimetinib development and industrial partnerships documented a period before authorisation. They are neither evidence of clinical efficacy nor a reason to choose a product. European authorisation dates to 2015: describing the approved combination today as merely \u201cpromising\u201d or still awaiting initial approval would be misleading.<\/p>\n<p>New uses, different combinations and strategies against resistance still require separate assessment. If offered in a clinical trial, clarify the phase, objective, participation criteria, risks and available alternatives. Enrolment does not guarantee personal benefit. The distinction between established use and research depends on the exact regimen and setting, not just the name cobimetinib.<\/p>\n<p class=\"im26-dg-sources\"><small>Sources for this section: <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cotellic\">EMA \u2014 Cotellic: indications, product information and leaflet<\/a>; <a href=\"https:\/\/www.cancer.gov\/research\/participate\/how\/treatment-trials\">National Cancer Institute \u2014 Participate in Cancer Treatment Trials<\/a>.<\/small><\/p>\n<\/section>\n<aside class=\"im26-dg-related\">\n<h2>Continue reading<\/h2>\n<ul>\n<li><a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/\">Medical treatment of melanoma<\/a><\/li>\n<li><a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/drugs-approved-for-melanoma\/\">Approved medicines for melanoma<\/a><\/li>\n<li><a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/braf-v600e\/\">BRAF V600E in melanoma<\/a><\/li>\n<li><a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/ipilimumab-yervoy\/\">Ipilimumab in melanoma<\/a><\/li>\n<li><a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/vemurafenib-2\/\">Vemurafenib in melanoma<\/a><\/li>\n<li><a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/dabrafenib-and-trametinib\/\">Dabrafenib and trametinib in melanoma<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/#med-sperimentali\">Experimental treatments: evidence, limitations and trial access<\/a><\/p>\n<\/aside>\n<section class=\"im26-dg-sources\">\n<h2>Sources and update<\/h2>\n<ul>\n<li><a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cotellic\">EMA \u2014 Cotellic: indications, product information and leaflet<\/a><\/li>\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25265494\/\">Larkin et al. \u2014 coBRIM, randomized phase 3 (2014)<\/a><\/li>\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39550033\/\">ESMO \u2014 Cutaneous melanoma: Clinical Practice Guideline (2024\/2025)<\/a><\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zelboraf\">EMA \u2014 Zelboraf: indications, product information and leaflet<\/a><\/li>\n<li><a href=\"https:\/\/www.cancer.gov\/research\/participate\/how\/treatment-trials\">National Cancer Institute \u2014 Participate in Cancer Treatment Trials<\/a><\/li>\n<\/ul>\n<p>Editorial revision and source consultation: 17 October 2026. Study dates distinguish current evidence from historical documents. This date does not certify specialist clinical review.<\/p>\n<\/section>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>MEK inhibition with vemurafenib: from historical trials to current use and safety monitoring.<\/p>\n","protected":false},"author":13,"featured_media":9715,"parent":5586,"menu_order":0,"comment_status":"open","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-9203","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cobimetinib in melanoma - Il Melanoma<\/title>\n<meta name=\"description\" content=\"Cobimetinib (formerly GDC-0973\/XL518) is a potent highly selective inhibitor of MEK also known as activated mitogen protein kinase.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/cobimetinib\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cobimetinib in melanoma - Il Melanoma\" \/>\n<meta property=\"og:description\" content=\"Cobimetinib (formerly GDC-0973\/XL518) is a potent highly selective inhibitor of MEK also known as activated mitogen protein kinase.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/cobimetinib\/\" \/>\n<meta property=\"og:site_name\" content=\"Il Melanoma\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-17T10:23:05+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/melanoma\\\/melanomas-medical-therapy\\\/cobimetinib\\\/\",\"url\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/melanoma\\\/melanomas-medical-therapy\\\/cobimetinib\\\/\",\"name\":\"Cobimetinib in melanoma - Il Melanoma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/melanoma\\\/melanomas-medical-therapy\\\/cobimetinib\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/melanoma\\\/melanomas-medical-therapy\\\/cobimetinib\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.ilmelanoma.com\\\/wp-content\\\/uploads\\\/2014\\\/10\\\/cobimetinib.jpg\",\"datePublished\":\"2014-10-11T13:31:03+00:00\",\"dateModified\":\"2026-10-17T10:23:05+00:00\",\"description\":\"Cobimetinib (formerly GDC-0973\\\/XL518) is a potent highly selective inhibitor of MEK also known as activated mitogen protein kinase.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/melanoma\\\/melanomas-medical-therapy\\\/cobimetinib\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/melanoma\\\/melanomas-medical-therapy\\\/cobimetinib\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/melanoma\\\/melanomas-medical-therapy\\\/cobimetinib\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.ilmelanoma.com\\\/wp-content\\\/uploads\\\/2014\\\/10\\\/cobimetinib.jpg\",\"contentUrl\":\"https:\\\/\\\/www.ilmelanoma.com\\\/wp-content\\\/uploads\\\/2014\\\/10\\\/cobimetinib.jpg\",\"width\":700,\"height\":394},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/melanoma\\\/melanomas-medical-therapy\\\/cobimetinib\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Melanoma\",\"item\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/melanoma\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Medical treatment of melanoma\",\"item\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/melanoma\\\/melanomas-medical-therapy\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Cobimetinib\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/\",\"name\":\"Il Melanoma\",\"description\":\"la guida alla conoscenza, prevenzione e cura del melanoma\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/#organization\",\"name\":\"Il Melanoma\",\"alternateName\":\"ilmelanoma.com\",\"url\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ilmelanoma.com\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/logo-melanoma-azzurro.png\",\"contentUrl\":\"https:\\\/\\\/www.ilmelanoma.com\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/logo-melanoma-azzurro.png\",\"width\":300,\"height\":29,\"caption\":\"Il Melanoma\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cobimetinib in melanoma - Il Melanoma","description":"Cobimetinib (formerly GDC-0973\/XL518) is a potent highly selective inhibitor of MEK also known as activated mitogen protein kinase.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/cobimetinib\/","og_locale":"en_US","og_type":"article","og_title":"Cobimetinib in melanoma - Il Melanoma","og_description":"Cobimetinib (formerly GDC-0973\/XL518) is a potent highly selective inhibitor of MEK also known as activated mitogen protein kinase.","og_url":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/cobimetinib\/","og_site_name":"Il Melanoma","article_modified_time":"2026-10-17T10:23:05+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/cobimetinib\/","url":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/cobimetinib\/","name":"Cobimetinib in melanoma - Il Melanoma","isPartOf":{"@id":"https:\/\/www.ilmelanoma.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/cobimetinib\/#primaryimage"},"image":{"@id":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/cobimetinib\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2014\/10\/cobimetinib.jpg","datePublished":"2014-10-11T13:31:03+00:00","dateModified":"2026-10-17T10:23:05+00:00","description":"Cobimetinib (formerly GDC-0973\/XL518) is a potent highly selective inhibitor of MEK also known as activated mitogen protein kinase.","breadcrumb":{"@id":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/cobimetinib\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/cobimetinib\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/cobimetinib\/#primaryimage","url":"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2014\/10\/cobimetinib.jpg","contentUrl":"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2014\/10\/cobimetinib.jpg","width":700,"height":394},{"@type":"BreadcrumbList","@id":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/cobimetinib\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Melanoma","item":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/"},{"@type":"ListItem","position":2,"name":"Medical treatment of melanoma","item":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/"},{"@type":"ListItem","position":3,"name":"Cobimetinib"}]},{"@type":"WebSite","@id":"https:\/\/www.ilmelanoma.com\/en\/#website","url":"https:\/\/www.ilmelanoma.com\/en\/","name":"Il Melanoma","description":"la guida alla conoscenza, prevenzione e cura del melanoma","publisher":{"@id":"https:\/\/www.ilmelanoma.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ilmelanoma.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.ilmelanoma.com\/en\/#organization","name":"Il Melanoma","alternateName":"ilmelanoma.com","url":"https:\/\/www.ilmelanoma.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ilmelanoma.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2023\/06\/logo-melanoma-azzurro.png","contentUrl":"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2023\/06\/logo-melanoma-azzurro.png","width":300,"height":29,"caption":"Il Melanoma"},"image":{"@id":"https:\/\/www.ilmelanoma.com\/en\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/pages\/9203","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/comments?post=9203"}],"version-history":[{"count":3,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/pages\/9203\/revisions"}],"predecessor-version":[{"id":11121,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/pages\/9203\/revisions\/11121"}],"up":[{"embeddable":true,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/pages\/5586"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/media\/9715"}],"wp:attachment":[{"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/media?parent=9203"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}